"uuid:ID","label","rationale","description","instanceType","name","id"
"bd03b9c1-adc6-4498-bd96-6bf9eedc2fd8","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign","Study Design 1","StudyDesign_1"
